Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30836047 | 0.84 | EPHX2 (0.36) | MAPTEPHX2 | |
| SCHEMBL28649530 | 0.82 | KCNH2 (0.37) | — | |
| SCHEMBL28658591 | 0.77 | CYP1A2 (0.40) | CYP1A2CYP3A4CYP2C19MAPTMAPK1 | |
| SCHEMBL28653697 | 0.72 | MAPT (0.39) | CYP1A2CYP3A4CYP2C19MAPTMAPK1 | |
| SCHEMBL12539750 | 0.71 | CYP1A2 (0.43) | CYP1A2CYP3A4CYP2C19MAPTMAPK1 | |
| SCHEMBL20636696 | 0.69 | MAPK1 (0.42) | CYP1A2CYP3A4CYP2C19MAPTMAPK1 | |
| SCHEMBL28650183 | 0.69 | CYP1A2 (0.37) | CYP1A2CYP3A4CYP2C19MAPTMAPK1 | |
| SCHEMBL28670348 | 0.69 | CYP1A2 (0.36) | CYP1A2CYP3A4CYP2C19MAPTMAPK1 | |
| SCHEMBL1535538 | 0.68 | RAPGEF4 (0.36) | — | |
| SCHEMBL28650491 | 0.68 | CYP1A2 (0.36) | CYP1A2CYP3A4CYP2C19MAPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109963851-B | Fused bicyclic pyridine compounds and their use as AMPA receptor modulators | 詹森药业有限公司 | 2021-11-30 | — | — | CN | disclosed |
| EP-3532477-B1 | FUSED BICYLIC PYRIDINE COMPOUNDS AND THEIR USE AS AMPA RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-08-26 | — | — | EP | disclosed |
| US-10087185-B2 | Fused bicylic pyridine compounds and their use as AMPA receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2018-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10087185-B2 | Fused bicylic pyridine compounds and their use as AMPA receptor modulators | GRIN1, GRIN3A, GRM1 | CYP1A2 1655/4885CYP3A4 868/4885CYP2C19 955/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.